Study guide

12.3 Cell Separations, Neutralization & Thiol Reagents

Specialist in Blood Banking, SBB ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB

2 Donors & Collection

2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations

3 Processing, Storage & Component QC

3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control

4 Red Cell & Modified Components

4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes

5 Platelets, Plasma & Cellular Products

5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors

6 Genetics, ABO & Rh

6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii

7 Other Blood Groups & Role in Transfusion

7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence

8 Immunology Foundations

8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement

9 Physiology, Hemostasis & HDFN

9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention

10 Cytopenias & Transplantation

10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation

11 Routine Serologic Testing

11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents

12 Special Serologic Methods

12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid

13 Molecular Platforms & Serologic QA

13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance

14 Indications, Component Therapy & PBM

14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management

15 Adverse Effects of Transfusion

15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases

16 Apheresis & Extracorporeal Circulation

16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation

17 Quality, Safety, Math & Instrumentation

17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation

18 Laboratory Administration (SBB Only)

18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management

12.3 Cell Separations, Neutralization & Thiol Reagents

Key Takeaways Explain This Topic AI

Cell-separation techniques (reticulocyte harvest, density gradient, differential hemolysis) resolve mixed-field reactions caused by transfused donor cells mixed with the patient's own population.

Neutralization uses soluble substances (saliva for Lewis, plasma for Chido/Rodgers, urine for Sda, hydatid cyst fluid for P1) to confirm antibody specificity by blocking it before testing.

DTT/2-ME cleave IgM's disulfide bonds, distinguishing IgM from IgG reactivity in cold agglutinin workups.

DTT-treated reagent red cells denature Kell antigens and CD38, resolving daratumumab drug interference, but cannot be used to rule out Kell antibodies.

ZZAP (DTT plus a proteolytic enzyme) combines antibody stripping and antigen reduction to improve autoadsorption efficiency.

Last updated: July 2026

Cell Separation Techniques

Some workups require physically distinguishing two red cell populations in the same specimen - most commonly the patient's own (autologous) cells mixed with previously transfused donor cells. This matters because a mixed-field reaction on routine typing can otherwise be misread as a weak or discrepant antigen result, and because true phenotype interpretation for antigen-matched transfusion requires knowing which cells are actually the patient's own.

Why donor and patient cells can be separated

Transfused donor red cells are a fixed cohort aging together (up to their ~120-day lifespan), while a patient recovering from hemorrhage or hemolysis is often producing a wave of younger, reticulocyte-rich red cells. This age/density difference is the basis for several separation methods:

Reticulocyte-harvest methods - a hypotonic wash or a microhematocrit-tube density separation concentrates the lighter, younger reticulocyte-rich fraction (more likely the patient's own regenerating cells) away from the denser, older transfused cohort.

Differential hemolysis - if patient and donor cells differ in an antigen with a readily available lysin (for example, an ABO-mismatched transfusion, where the other blood type's cells can be selectively lysed with anti-A or anti-B), the unwanted population can be destroyed, leaving the population of interest for testing.

Density-gradient separation - dextran or similar media separate cell populations by density in a manner similar to reticulocyte harvesting, useful when the age/density difference is the clearest distinguishing feature.

Worked example

A group O patient was transfused two units of group O, Fy(a+) red cells five days ago. A routine antibody screen now shows a mixed-field reaction with anti-Fya antiserum: some cells agglutinate strongly, others do not. Rather than reporting a confusing "weak positive," the technologist recognizes the mixed-field pattern as two red cell populations - donor Fy(a+) cells and the patient's own presumably Fy(a-) cells - and uses a reticulocyte-harvest separation to concentrate the patient's own younger cells before retesting, confirming the patient's true Duffy phenotype rather than reporting a result contaminated by transfused cells.

Neutralization Studies

Neutralization exploits the fact that some blood group antigens exist as soluble substances in body fluids as well as on the red cell membrane. Adding the correct soluble substance to serum before testing will neutralize (bind up) the corresponding antibody, and the antibody's reactivity weakens or disappears - confirming its specificity.

  • Soluble Substance Antibody Neutralized
  • Saliva from a Le(a+b-) or Le(a-b+) secretor Anti-Lea or anti-Leb
  • Pooled human plasma Anti-Ch (Chido) / anti-Rg (Rodgers)
  • Concentrated human urine Anti-Sda
  • Hydatid cyst fluid or pigeon egg white Anti-P1
  • Worked example and caution

A panel shows weak, variable reactions suggestive of anti-Lea. Adding Le(a+) saliva to an aliquot of the patient's serum before retesting causes the reactivity to disappear, confirming anti-Lea . However, neutralization only confirms the presence of that one antibody - it does not rule out a coexisting clinically significant alloantibody hiding in the same serum. In a prenatal patient, for example, a full antibody identification workup must still be completed even after Lewis-antibody neutralization is confirmed, because Lewis antibodies themselves are generally not clinically significant, but a second, significant antibody could still be present.

Thiol Reagents: DTT and 2-Mercaptoethanol

Dithiothreitol (DTT) and 2-mercaptoethanol (2-ME) are reducing agents that cleave disulfide bonds. In the blood bank they are applied in two distinct ways:

1. Treating serum - differentiating IgM from IgG

DTT/2-ME break the disulfide bonds holding IgM pentamers together, converting IgM into non-agglutinating monomeric subunits. Treating serum with DTT and then retesting is a way to determine whether an antibody's reactivity is due to IgM, IgG, or both: reactivity that disappears after DTT treatment was IgM; reactivity that persists indicates an IgG component. This is especially useful in cold agglutinin workups, where a strong IgM autoagglutinin can mask a clinically significant IgG alloantibody.

2. Treating reagent red cells - denaturing Kell and unmasking drug interference

DTT treatment of red cells denatures the Kell glycoprotein , destroying Kell system antigens (K, k, Kpa, Kpb, Jsa, Jsb) while leaving ABO, Rh, Kidd, Lewis, MNS, and Duffy intact. DTT-treated ('Kell-negative-like') reagent cells have a specific, heavily tested application: patients receiving daratumumab , an anti-CD38 monoclonal antibody used to treat multiple myeloma, show panreactive antibody-screen results because daratumumab binds CD38 on every reagent red cell. DTT denatures CD38, eliminating this drug interference and allowing any true underlying alloantibody to be seen. The tradeoff is that DTT-treated cells can never be used to confirm or rule out a Kell-system antibody, since the Kell antigens themselves are destroyed in the process.

ZZAP reagent , mentioned earlier for autoadsorption, is simply DTT combined with a proteolytic enzyme (papain or ficin). The dual action strips bound antibody from the cell membrane (via DTT) while also reducing surface antigen density (via the enzyme), which improves the efficiency of each round of autoadsorption and reduces the number of adsorption cycles needed to remove a strong autoantibody.